COCRYSTAL PHARMA, INC. Revenue from Contract with Customer, Excluding Assessed Tax
COCRYSTAL PHARMA, INC. (COCP) reported Revenue from Contract with Customer, Excluding Assessed Tax of $498.00 thousand for the 1-month period ending 2025-09-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- COCRYSTAL PHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-12-31 was $510.00K, a 26.87% increase year-over-year.
- COCRYSTAL PHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-09-30 was $489.00K, a 0.61% decline year-over-year.
- COCRYSTAL PHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-06-30 was $554.00K, a 6.42% decline year-over-year.
- COCRYSTAL PHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-03-31 was $461.00K, a 90.92% decline year-over-year.
- COCRYSTAL PHARMA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $2.01M, a 69.32% decline from fiscal 2019.
- COCRYSTAL PHARMA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $6.56M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 1 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | $498.00K 10-Q · filed 2026-08-13 | ||||
| 2020-12-31 | $510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $999.00K derived: sum of 2 quarters · filed 2022-03-23 | $1.55M derived: sum of 3 quarters · filed 2022-03-23 | $2.01M 10-K · filed 2022-03-23 | |
| 2020-09-30 | $489.00K 10-Q · filed 2021-11-15 | $1.04M derived: sum of 2 quarters · filed 2021-11-15 | $1.50M 10-Q · filed 2021-11-15 | $1.91M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $554.00K 10-Q · filed 2021-08-16 | $1.01M 10-Q · filed 2021-08-16 | $1.42M derived: sum of 3 quarters · filed 2021-08-16 | $1.91M derived: sum of 4 quarters · filed 2021-08-16 | |
| 2020-03-31 | $461.00K 10-Q · filed 2021-05-17 | $863.00K derived: sum of 2 quarters · filed 2021-05-17 | $1.35M derived: sum of 3 quarters · filed 2021-05-17 | $1.95M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $894.00K derived: sum of 2 quarters · filed 2021-03-17 | $1.49M derived: sum of 3 quarters · filed 2021-03-17 | $6.56M 10-K · filed 2021-03-17 | |
| 2019-09-30 | $492.00K 10-Q · filed 2020-11-13 | $1.08M derived: sum of 2 quarters · filed 2020-11-13 | $6.16M 10-Q · filed 2020-11-13 | ||
| 2019-06-30 | $592.00K 10-Q · filed 2020-08-06 | $5.67M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $5.08M 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |